Radiopharmaceutical Theranostics Market Worth $3.44 Billion, Globally, by 2028 at 11.3% CAGR | The Insight Partners
29 mars 2023 10h15 HE
|
The Insight Partners
Pune, India, March 29, 2023 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on "Radiopharmaceutical Theranostics Market Size, Share, Revenue, Growth Strategy, Industry...
POINT Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Highlights
27 mars 2023 08h00 HE
|
POINT Biopharma
Signed Strategic Collaboration Agreement with Lantheus Holdings Inc. for POINT's PNT2002 and PNT2003 product candidates Completed enrollment for randomization phase of PNT2002's phase 3 SPLASH...
ITM, Helmholtz Munich and University Hospital Münster Announce Start of Phase I Clinical Trial with Radiotherapeutic ITM-31 for Glioblastoma
13 mars 2023 06h13 HE
|
ITM Isotope Technologies Munich SE
Garching/Munich, Munich and Münster, Germany, March 13, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, Helmholtz Munich and the Departments of...
Global Nuclear Medicine Imaging Equipment Strategic Report 2023: PET-MRI Emerging as a Promising Standard for Imaging Soft Tissue Contrast
07 mars 2023 12h13 HE
|
Research and Markets
Dublin, March 07, 2023 (GLOBE NEWSWIRE) -- The "Nuclear Medicine Imaging Equipment: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market...
POINT Biopharma Confirms No Disruptions to the Manufacturing and Clinical Supply for the 177Lu-PNT2002 SPLASH Trial, a Phase 3 Study in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)
07 mars 2023 07h45 HE
|
POINT Biopharma
INDIANAPOLIS, March 07, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
POINT Biopharma to Participate in Upcoming Investor Conferences
02 févr. 2023 08h30 HE
|
POINT Biopharma
INDIANAPOLIS, Feb. 02, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
POINT Biopharma Completes Randomization in PNT2002’s Phase 3 SPLASH Trial
12 janv. 2023 08h30 HE
|
POINT Biopharma
INDIANAPOLIS, Jan. 12, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
ITM to Present at the 41st Annual J.P. Morgan Healthcare Conference
03 janv. 2023 10h30 HE
|
ITM Isotope Technologies Munich SE
Garching / Munich, January 03, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that CEO Steffen Schuster and CFO Dr. Klaus Maleck will...
POINT Biopharma Releases New Preclinical Data Supporting the Combination of 177Lu-PNT6555 with Immunotherapy
29 nov. 2022 07h30 HE
|
POINT Biopharma
Combining 177Lu-PNT6555 with anti-PD-1 immunotherapy resulted in a significantly increased survival benefit compared to independent treatments in an anti-PD-1 resistant preclinical tumor model ...
Outlook on the Nuclear Medicine Global Market to 2028: Use of Radiopharmaceuticals in Neurological Applications Presents Opportunities
16 nov. 2022 04h08 HE
|
Research and Markets
Dublin, Nov. 16, 2022 (GLOBE NEWSWIRE) -- The "Nuclear Medicine Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2028" report has been added to ResearchAndMarkets.com's...